Asian populations are under-represented in human genomics research. Here, we
characterize clinically significant genetic variation in 9051 genomes representing East …

Introduction The technological advances of sequencing methods during the past 20 years
have fuelled the generation of large amounts of sequencing data that comprise common …

Dual antiplatelet therapy (DAPT) has been the mainstay treatment to reduce ischemic
events, such as myocardial infarction or stroke, in patients with coronary artery disease …

Pharmacogenomic testing may be used to improve treatment outcomes and reduce the
frequency of adverse drug reactions (ADRs). Population specific, targeted …

Abstract Background Pharmacogenomics (PGx) examines the influence of genetic variation
on drug responses. With more and more Clinical Pharmacogenetics Implementation …

Exome sequencing is utilized in routine clinical genetic diagnosis. The technical robustness
of repurposing large-scale next-generation sequencing data for pharmacogenetics has …

Objective Pharmacogenomics (PGx) is a clinically significant factor in the safe and
efficacious use of medicines. While PGx knowledge is abundant for other populations, there …

Background Different levels of evidence related to the variable responses of individuals to
drug treatment have been reported in various pharmacogenomic (PGx) databases …

Simple Summary High-dose methotrexate is commonly used to treat several types of cancer.
While effective, elimination of high-dose methotrexate from the body is highly variable and …

The implementation of pharmacogenetics (PGx) is a main milestones of precision medicine
nowadays in order to achieve safer and more effective therapies. Nevertheless, the …